Medical Marketing Int'l Group PLC
20 February 2004


FOR IMMEDIATE RELEASE 20 FEBRUARY 2004


MMI TO BE GRANTED

US PATENT FOR ANTI CANCER THERAPY


Medical Marketing International Group plc ('MMI') the Cambridge, UK-based
technology management company focussed on the bio-therapeutic sector (LSE : MMG)
announces that it has been formally notified by the US Patent Office that the
patent for its ruthenium anti-cancer therapy, being developed by MMI's
wholly-owned cancer therapy subsidiary Oncosense, will be granted.

MMI announced on 28th October 2003 that it had received notification by the
European Patent Office that the ruthenium patent would be granted in the
European territories.

On 18th September 2003 MMI announced that the Oncosense ruthenium compounds had
the potential to be a whole new class of cancer therapy showing potency at least
as good as the market-leading therapies carboplatin and cisplatin and with the
potential for reduced toxicity, a novel mechanism of action and non-cross
resistance. Additionally data showed that the ruthenium compounds each have
their own spectrum of activity, with individual compounds showing differential
activity against individual cell lines including non-small cell lung cancer,
breast cancer and melanoma.

Mark Burton, Technology Manager at MMI, commenting on today's announcement said:
'We are delighted to have received notification that the ruthenium patent will
grant in the world's biggest cancer therapy market. When added to the European
patent notification this means that we will have protection in two of the
world's largest markets. This news coupled with our technical progress with
ruthenium considerably strengthens our commercial position in the global cancer
therapy market which is worth some $20bn'.


For further information, please contact:

David Best - Executive Chairman
MMI Group Tel: +44 (0)1223 477677

www.mmigroup.co.uk

Lisa Baderoon
Buchanan Communications Tel: +44 (0)20 7466 5000
lisab@buchanan.uk.com


This information is provided by RNS
The company news service from the London Stock Exchange

The outlook of ruthenium compounds is outstanding. Buy MMI at 76p.

Another big rise on no new news.. whats happening..?